How long will it take for sparsentan/sparsentan to be available in China?

Sparsentan is a new type of drug mainly used to treat primary immunoglobulin A nephropathy (IgAN). Its mechanism of action is to slow down the progression of the disease by reducing proteinuria. In February 2023, the drug was approved by the U.S. Food and Drug Administration (FDA) and became a first-class drug, marking its important position in the field of kidney disease treatment. However, as of January 2025, Sparsentin has not yet been launched in China, and the specific launch time is still unclear.

Before drugs enter the Chinese market, they need to go through a complex approval process. First, drug companies must submit a registration application, including clinical trial data, drug production information, etc., to China’s National Medical Products Administration (NMPA). The review of these materials usually takes a long time and involves multiple stages, including preliminary review, expert review, and publicity. In these links, on the one hand, it is necessary to ensure the safety and effectiveness of the drug, and on the other hand, it is also necessary to evaluate its adaptability to the Chinese market.

Clinical research data of sparsentan show that it is better than traditional therapeutic drugs such as irbesartan in reducing proteinuria inIgAN patients, which makes it very promising in the treatment of kidney disease. And, as the first non-immunosuppressive therapy, sparsentan has unique advantages in treating high-risk patients. These features may attract the attention of NMPA, thereby speeding up its approval process in China.

However, the use of sparsentane is also associated with certain risks, such as hepatotoxicity and embryo-fetal toxicity. These potential adverse reactions may affect the market acceptance and launch process of the drug, so during the application process, companies need to provide sufficient safety data to obtain regulatory approval.

Reference materials:https://en.wikipedia.org/wiki/Sparsentan